By Billy Candra 
For physicians dedicated to the long-term well-being of childhood cancer survivors, a critical new understanding has emerged: a survivor’s genetic makeup, in conjunction with their life-saving past cancer treatments, significantly shapes their vulnerability to developing secondary cancers. This groundbreaking revelation stems from meticulous research conducted by scientists at St. Jude Children’s Research Hospital. Their work, published in the esteemed journal The Lancet Oncology, marks a pivotal moment by precisely quantifying the individual contributions of various factors to the risk of a second malignancy—a formidable threat that remains the leading cause of mortality for these long-term survivors.
The genesis of this profound insight lies within the unparalleled datasets of the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS), two of the globe’s foremost longitudinal investigations into childhood cancer survivorship, both expertly stewarded at St. Jude. These expansive studies have provided an unprecedented canvas for researchers to delineate the intricate interplay of genetic predispositions and treatment exposures in shaping future health trajectories.
The Growing Challenge of Survivorship: A Historical Perspective
Decades of relentless progress in pediatric oncology have dramatically transformed the landscape of childhood cancer. What was once a near-certain death sentence for many forms of the disease has, through advancements in chemotherapy, radiation therapy, and surgical techniques, become a journey with increasingly hopeful outcomes. Today, more than 80% of children diagnosed with cancer will survive five years or more. This triumph, however, has brought forth a new, complex challenge: the long-term health consequences for these survivors. As millions of individuals who conquered childhood cancer reach adulthood, they often contend with a spectrum of "late effects" from their intensive treatments. These late effects can manifest as cardiovascular problems, endocrine disorders, neurocognitive deficits, and, crucially, an elevated risk of developing secondary cancers—new, unrelated malignancies that emerge years or even decades after the original diagnosis.
Historically, the medical community’s understanding of secondary cancer risk was heavily weighted towards treatment exposures, particularly the known mutagenic effects of radiation and certain chemotherapeutic agents. While this understanding was foundational, it lacked the granular detail of precisely how much each factor contributed, especially when considered alongside the inherent genetic variability within the patient population. This knowledge gap left clinicians and patients with an incomplete picture of individual risk, hindering the development of truly personalized surveillance and prevention strategies. The St. Jude study now addresses this lacuna, offering a more holistic and quantified perspective.
A Landmark Study Unveiled: Quantifying the Contributions
The St. Jude research represents a monumental leap forward by moving beyond mere associations to attributions of risk. "We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated Dr. Yadav Sapkota, corresponding author and a distinguished member of the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification is crucial for refining risk models and guiding clinical decisions.
To achieve this, St. Jude scientists meticulously analyzed data from over 10,000 survivors drawn from the St. Jude LIFE and CCSS cohorts, which collectively form the largest survivor cohort in North America. This colossal dataset encompassed a wealth of information, including detailed records of prior treatment exposures (type, dose, field), comprehensive genetic information (both common and rare variants), lifestyle factors (such as diet and exercise habits), and, critically, the documented presence or absence of secondary cancers. This unparalleled depth and breadth of data allowed the researchers to disentangle the complex web of factors influencing secondary cancer development. Co-author Dr. Greg Armstrong, chair of the St. Jude Department of Epidemiology and Cancer Control, underscored the unique capabilities of these cohorts, noting, "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing."
Deconstructing the Risk: Radiation, Chemotherapy, and Genetics
The study meticulously dissected the contributions of various elements to secondary cancer risk, yielding results that both confirmed established understanding and challenged conventional wisdom.
Radiation Exposure: The Dominant Factor
Unsurprisingly, radiation exposure emerged as the most significant single contributor to secondary cancer risk, accounting for approximately 40% or more of the overall risk. This finding aligns with decades of prior research that has extensively documented the long-term adverse effects of radiation, including its carcinogenic potential. The study’s robust quantification further reinforces the ongoing efforts in modern pediatric oncology to minimize radiation doses or eliminate radiation exposure entirely when other effective treatments are available. Over the past several decades, therapeutic protocols for many childhood cancers, such as Hodgkin lymphoma and certain brain tumors, have been successfully de-escalated in terms of radiation intensity or substituted with chemotherapy-only regimens, precisely to mitigate these long-term sequelae. This research provides strong empirical support for the continued pursuit of such radiation-sparing strategies.
Chemotherapy’s Variable Impact
The researchers observed a more complex relationship between chemotherapy and secondary cancer risk. Depending on the specific type of subsequent cancer, chemotherapy contributed anywhere from 8% to 35% of the risk. While the late effects of various chemotherapeutic agents—such as anthracyclines, alkylating agents, and topoisomerase inhibitors—have been well-described and are known to contribute to secondary leukemias and solid tumors, the exact proportional contribution across the survivor population had not been previously quantified at this scale. The variability in its impact underscores the heterogeneous nature of chemotherapy regimens and their distinct biological mechanisms of action and toxicity profiles.
The Surprising Power of Genetics
Perhaps the most striking and novel revelation of the study concerned the substantial and, at times, overriding influence of genetic predisposition. The contribution of genetic factors to secondary cancer risk in survivors has historically been less recognized or systematically quantified compared to treatment exposures. To better understand this predisposition, the St. Jude team investigated two categories of genetic variants: hundreds of common genetic variants previously linked to cancer development in the general population, which were aggregated into a "polygenic risk score" (PRS), and certain rare genetic variants.
A polygenic risk score is a sophisticated measure that combines the effects of many common genetic variants, each contributing a small amount to the overall risk of a disease. By analyzing these scores in the St. Jude LIFE and CCSS participants, the researchers found that the polygenic risk score contributed between 5% and 37% of the risk, depending on the specific type of secondary cancer.
Dr. Yutaka Yasui, also from the St. Jude Department of Epidemiology and Cancer Control and a co-author on the study, commented on the utility of PRS: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This suggests that while PRS might have limitations in general population screening, its predictive power is significantly enhanced when integrated with the known exposures of childhood cancer survivors.
The magnitude of this genetic contribution challenged prevailing assumptions. Dr. Sapkota emphasized this paradigm shift: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This statement highlights the profound implications for how clinicians and researchers should approach risk stratification in the future.
Lifestyle Factors: A Nuanced Role
In contrast to the significant roles of treatment and genetics, lifestyle factors—such as diet, physical activity levels, and body mass index—appeared to contribute much less to secondary cancer risk in this cohort, accounting for a modest 1% to 6% of the risk. However, the researchers cautioned against drawing definitive long-term conclusions from this finding. The survivor population in this study was predominantly in their 20s and 30s, an age range where the cumulative effects of lifestyle choices on cancer development may not yet be fully apparent. Many cancers, particularly solid tumors, often have long latency periods, requiring decades for lifestyle-related risks to manifest.
Dr. Sapkota clarified, "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage—and patients to seek—a healthy lifestyle." This underscores that while lifestyle’s direct impact on secondary cancer risk might be subtle in younger adults, its broader benefits for overall health and other late effects remain critical.
Redefining Clinical Care: Implications for Patients and Physicians
The findings of this landmark study carry substantial implications for the clinical management and long-term surveillance of childhood cancer survivors. The traditional approach, which predominantly focused on treatment exposures when assessing secondary cancer risk, must now evolve to incorporate a more comprehensive understanding of genetic predisposition.
"Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota observed. "Our study suggests that we need to better account for genetic predisposition in this population." This shift implies a future where genetic screening could become a more integral part of survivorship care. Survivors identified with a strong genetic predisposition, perhaps through enhanced polygenic risk scores or the presence of specific rare variants, could benefit from more personalized and intensified cancer screenings. This proactive approach aims to detect any emerging secondary cancers at their earliest, most treatable stages, significantly improving prognoses.
For patients, this new knowledge offers empowerment. Survivors, armed with a deeper understanding of their unique combination of treatment-related, genetic, and lifestyle risk factors, will be better equipped to engage in informed discussions with their healthcare providers. They can advocate more effectively for tailored screening protocols and personalized care plans that reflect their individual risk profiles. This collaborative approach fosters shared decision-making, placing the survivor at the center of their long-term health management. The study could also prompt the development of clearer guidelines from major oncology organizations, offering standardized yet flexible frameworks for incorporating genetic information into survivorship care.
The Path Forward: Prevention, Detection, and Extended Lives
Secondary cancers persist as the foremost cause of mortality for individuals who successfully navigate childhood cancer. By meticulously quantifying the contributions of treatment, genetics, and, to a lesser extent, lifestyle factors to this devastating risk, the St. Jude research team has provided an invaluable roadmap. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives," concluded Dr. Sapkota.
This study not only illuminates the complex interplay of risk factors but also opens new avenues for targeted interventions. Future research will undoubtedly focus on refining polygenic risk scores, identifying additional actionable genetic variants, and developing more precise risk prediction models that can seamlessly integrate into clinical practice. The ultimate goal remains steadfast: to leverage this enriched understanding to mitigate the burden of secondary cancers, enhance the quality of life, and extend the healthy lifespans of the growing population of childhood cancer survivors, ensuring their hard-won victories over cancer are truly lifelong.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors include Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison, and Yutaka Yasui from St. Jude; Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte, and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center; and Smita Bhatia from the University of Alabama at Birmingham.
This critical research was made possible through generous support from grants provided by the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547, and CA21765) and ALSAC, the dedicated fundraising and awareness organization that sustains St. Jude Children’s Research Hospital.
